Anticoagulation in Temporal Cavernous Malformations

Guideline Context for Anticoagulation Decisions

The American College of Physicians suggests that absolute contraindications to anticoagulation include active major bleeding, recent intracranial hemorrhage, and severe thrombocytopenia, which would preclude its use in patients with temporal cavernous malformations 1
Relative contraindications requiring careful risk-benefit assessment include high risk for falls, recent major surgery, and moderate thrombocytopenia, as indicated by clinical guidelines 1

The American Heart Association indicates that deeply situated cavernomas carry higher baseline hemorrhage risk than superficial lesions like temporal lobe cavernomas, with an estimated annual hemorrhage rate of 3.3-4.5% 2, 3
Temporal lobe location is considered superficial and therefore at lower baseline hemorrhage risk compared to deep structures, according to the American Stroke Association 2

The American College of Cardiology recommends assessing for absolute contraindications and evaluating the indication for anticoagulation in patients with temporal cavernous malformations requiring anticoagulation 1, 4
Consideration of lesion characteristics, such as prior hemorrhage and multiple cavernomas, is crucial in determining the risk-benefit ratio of anticoagulation, as suggested by the American Academy of Neurology 2, 3

The use of MRI with T2-weighted gradient-echo or susceptibility-weighted imaging is recommended to identify additional lesions and assess the risk of hemorrhage in patients with temporal cavernous malformations 3, 5

The American College of Radiology recommends withholding anticoagulation only if absolute contraindications exist, such as active major bleeding, recent intracranial hemorrhage, severe thrombocytopenia, or severe bleeding diathesis 6
The American Society of Hematology defines severe thrombocytopenia as a platelet count less than 50,000/mL, which is a contraindication for anticoagulation 7

The American Heart Association recommends proceeding with anticoagulation if there is a strong indication, such as cardioembolic stroke prevention, acute venous thromboembolism, or high-risk cardiac conditions requiring anticoagulation 8
The Congress of Neurological Surgeons suggests considering lesion-specific risk factors, such as prior hemorrhage, multiple cavernomas, and lesion size and characteristics on MRI, but these factors should not automatically preclude anticoagulation 9

The Congress of Neurological Surgeons recommends exercising heightened vigilance in patients with brainstem cavernomas, recent symptomatic hemorrhage, or familial cases with CCM3 mutations 9

The American College of Radiology recommends maintaining therapeutic anticoagulation levels, such as INR 2.0-3.0 for warfarin, rather than supratherapeutic levels 6
The American Society of Hematology recommends reassessing the risk-benefit ratio if acute symptomatic hemorrhage occurs while on anticoagulation, development of severe thrombocytopenia, or major bleeding from any source requiring hospitalization or transfusion 6, 7